published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted disease with increasing prevalence and profound ...

The American College of Clinical Pharmacology® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists". Obesity is a multifaceted ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, ...

A New Tool for Researchers Developing Dual- and Triple-Agonist Therapies for Obesity, Diabetes, and Other Metabolic ... its already popular Glucagon-like Peptide-1 Receptor (GLP-1R) and Gastric ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...